Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma

References

• National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN Guidelines(R)): Multiple Myeloma Version 1.2015. Fort Washington, PA: National Comprehensive Cancer Network, 2014. http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed September 22, 2014
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29
   PubMed Web of Science ®Google Scholar
• SEER. SEER stat fact sheets: myeloma. Bethesda, MD: SEER, 2014. http://seer.cancer.gov/statfacts/html/mulmy.html. Accessed September 22, 2014
   Google Scholar
• Kristinsson SY, Anderson WF, Landgren O. Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia 2014;28:1346-8
   PubMed Web of Science ®Google Scholar
• Pulte D, Redaniel MT, Brenner H, et al. Recent improvement in survival of patients with multiple myeloma: variation by ethnicity. Leuk Lymphoma 2014;55:1083-9
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28:1122-8
   PubMed Web of Science ®Google Scholar
• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-60
   PubMed Web of Science ®Google Scholar
• Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014;371:906-17
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 2013;31:448-55
   PubMed Web of Science ®Google Scholar
• Kumar A, Hozo I, Wheatley K, et al. Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review. Am J Hematol 2011;86:18-24
   PubMed Web of Science ®Google Scholar
• Picot J, Cooper K, Bryant J, et al. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation. Health Technol Assess 2011;15:1-204
   Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17
   PubMed Web of Science ®Google Scholar
• Mateos MV, Richardson PG, Shi H, et al. Higher cumulative bortezomib dose results in better Overall Survival (OS) in patients with previously untreated Multiple Myeloma (MM) receiving bortezomib-melphalan-prednisone (VMP) in the phase 3 VISTA study. Blood 2013;122:1968
   Web of Science ®Google Scholar
• Garrison LP, Jr Wang ST, Huang H, et al. The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. Oncologist 2013;18:27-36
   PubMed Web of Science ®Google Scholar
• Weisel K, Doyen C, Dimopoulos MA, et al. P645 - A systematic literature review and network meta-analysis of treatments for patients with transplant-ineligible newly diagnosed multiple myeloma. Paper presented at: 20th Annual European Hematology Association Congress; June 11–14, 2015; Vienna, Austria
   Google Scholar
• Sacchi S, Marcheselli R, Lazzaro A, et al. A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. Leuk Lymphoma 2011;52:1942-8
   PubMed Web of Science ®Google Scholar
• Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209-18
   PubMed Web of Science ®Google Scholar
• Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009;27:3664-70
   PubMed Web of Science ®Google Scholar
• Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010;28:2259-66
   PubMed Web of Science ®Google Scholar
• Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics 2007;25:3-6
   PubMed Web of Science ®Google Scholar
• Wolters Kluwer Health. Medi-Span Drug Information Database, average wholesale acquisition cost. Greenwood Village, CO: Wolters Kluwer Health, 2014. http://www.medispan.com/average-wac-pricing-file/. Accessed September, 2014
   Google Scholar
• Truven Health Analytics. RED BOOK Online®. Baltimore, MD: Truven Health Analytics, 2014. http://micromedex.com/products/product-suites/clinical-knowledge/redbook. Accessed July 16, 2014
   Google Scholar
• Centers for Medicare & Medicaid Services (CMS). Average Sales Price (ASP) Pricing File. Payment Allowance Limits for Medicare Part B Drugs. Effective July 1, 2014 through September 30, 2014. Baltimore, MD: Centers for Medicare & Medicaid Services, 2014. http://www.cms.gov/. Accessed November, 2014
   Google Scholar
• Centers for Medicare & Medicaid Services (CMS). Administrative cost. Hospital Outpatient Prospective Payment System. 2014 File. Payment Rate. Baltimore, MD: Centers for Medicare & Medicaid Services, 2014. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html. Accessed November, 2014
   Google Scholar
• Brown GC, Brown MM, Menezes A, et al. Cataract surgery cost utility revisited in 2012: a new economic paradigm. Ophthalmology 2013;120:2367-76
   PubMed Web of Science ®Google Scholar
• Calhoun EA, Chang CH, Welshman EE, et al. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist 2001;6:441-5
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Maroun J, Shah A. Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis. Support Care Cancer 2005;13:318-24
   PubMed Web of Science ®Google Scholar
• Dworkin RH, White R, O'Connor AB, et al. Health care expenditure burden of persisting herpes zoster pain. Pain Med 2008;9:348-53
   PubMed Web of Science ®Google Scholar
• Eber MR, Laxminarayan R, Perencevich EN, et al. Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia. Arch Intern Med 2010;170:347-53
   PubMed Web of Science ®Google Scholar
• Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004;164:1653-61
   PubMed Web of Science ®Google Scholar
• Gatchel RJ, Polatin PB, Noe C, et al. Treatment- and cost-effectiveness of early intervention for acute low-back pain patients: a one-year prospective study. J Occup Rehabil 2003;13:1-9
   PubMed Web of Science ®Google Scholar
• Goulart B, Ramsey S. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health 2011;14:836-45
   PubMed Web of Science ®Google Scholar
• Nichols GA, Arondekar B, Herman WH. Medical care costs one year after identification of hyperglycemia below the threshold for diabetes. Med Care 2008;46:287-92
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Clarke L, Kamath TV, et al. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan. J Manag Care Pharm 2006;12:472-8
   PubMed Web of Science ®Google Scholar
• Singh G, Lingala V, Wang H, et al. Use of health care resources and cost of care for adults with constipation. Clin Gastroenterol Hepatol 2007;5:1053-8
   PubMed Web of Science ®Google Scholar
• Sorensen S, Ellis L, Wu Y, et al. Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. J Manag Care Pharm 2013;19:799-808
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services (CMS). Clinical Diagnostic Laboratory Fee Schedule. National Limit Payment. Baltimore, MD: Centers for Medicare & Medicaid Services, 2014. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.html. Accessed November, 2014
   Google Scholar
• Kropff M, Baylon HG, Hillengass J, et al. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica 2012;97:784-91
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Weber DM, Niesvizky R, et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol 2009;82:426-32
   PubMed Web of Science ®Google Scholar
• Delforge M, Minuk L, Eisenmann JC, et al. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica 2015;100:826-33
   PubMed Web of Science ®Google Scholar
• Delforge M, Dhawan R, Robinson D, Jr, et al. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol 2012;89:16-27
   PubMed Web of Science ®Google Scholar
• Proskorovsky I, Lewis P, Williams CD, et al. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health Qual Life Outcomes 2014;12:35
   PubMed Web of Science ®Google Scholar
• Cavenagh JD, Belch AR, Hulin C, et al. Cost-effectiveness in newly diagnosed multiple myeloma (NDMM): Lenalidomide plus low-dose dexamethasone (Rd) versus bortezomib plus melphalan and prednisone (VMP). Milan, Italy: European Hematology Association, 2014
   Google Scholar
• Elkin EB, Weinstein MC, Winer EP, et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2004;22:854-63
   PubMed Web of Science ®Google Scholar
• Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. Mayo Clin Proc 2012;87:935-43
   PubMed Web of Science ®Google Scholar
• Griffiths RI, Gleeson ML, Mikhael J, et al. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma. Cancer 2012;118:6079-88
   PubMed Web of Science ®Google Scholar
• Handorf EA, McElligott S, Vachani A, et al. Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung. J Oncol Pract 2012;8:267-74
   PubMedGoogle Scholar
• Shankaran V, Mummy D, Koepl L, et al. Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer. Oncologist 2014;19:892-9
   PubMed Web of Science ®Google Scholar
• Ubel PA, Berry SR, Nadler E, et al. In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival. Health Aff (Millwood) 2012;31:709-17
   PubMed Web of Science ®Google Scholar
• Giacomini M. How good is good enough? Standards in policy decisions to cover new health technologies. Healthc Policy 2007;3:91-101
   PubMedGoogle Scholar
• Wang ST, Huang H, Ba-Mancini A, et al. The cost-effectiveness of bortezomib plus melphalan and prednisone versus lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment for the initial treatment of multiple myeloma in the United States. Blood 2010;116:2563
   Web of Science ®Google Scholar
• Kim MY, Sposto R, Swaika A, et al. Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma. Oncology 2014;87:224-31
   PubMed Web of Science ®Google Scholar
• Arikian SR, Milentijevic D, Binder G, et al. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma. Curr Med Res Opin 2015;31:1105-15
   PubMed Web of Science ®Google Scholar
• Gaultney JG, Uyl-de Groot CA. Efficient allocation of novel agents in multiple myeloma: a work in progress. Oncologist 2013;18:5-7
   PubMed Web of Science ®Google Scholar